Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CORBFNASDAQ:OPGNNASDAQ:SERANASDAQ:XGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCORBFGlobal Cord Blood$1.09+3.8%$0.96$0.25▼$2.00$132.49M-0.64164,114 shs5,041 shsOPGNOpGen$4.98-3.3%$3.37$0.53▼$5.30$41.61M-1.7110,901 shs13,279 shsSERASera Prognostics$2.41-4.4%$3.56$2.36▼$10.23$90.70M0.99131,218 shs224,161 shsXGNExagen$6.83+6.4%$4.43$1.35▼$7.20$122.95M1.598,789 shs699,725 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCORBFGlobal Cord Blood+3.81%+3.81%-5.22%+9.00%-12.80%OPGNOpGen-0.58%+3.21%+28.75%+415.00%+7.07%SERASera Prognostics-10.00%-15.44%-21.00%-50.00%-74.60%XGNExagen+2.72%-6.69%+59.31%+20.45%+365.22%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCORBFGlobal Cord BloodN/AN/AN/AN/AN/AN/AN/AN/AOPGNOpGenN/AN/AN/AN/AN/AN/AN/AN/ASERASera Prognostics1.3502 of 5 stars0.04.00.00.03.62.50.0XGNExagen3.8583 of 5 stars2.53.00.04.52.43.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCORBFGlobal Cord Blood 0.00N/AN/AN/AOPGNOpGen 0.00N/AN/AN/ASERASera Prognostics 3.00BuyN/AN/AXGNExagen 3.00Buy$7.509.81% UpsideCurrent Analyst Ratings BreakdownLatest OPGN, CORBF, XGN, and SERA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2025XGNExagenBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/12/2025XGNExagenWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform(Data available from 5/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCORBFGlobal Cord Blood$196.12M0.68$0.78 per share1.40N/A∞OPGNOpGen$2.67M15.57N/AN/A($11.55) per share-0.43SERASera Prognostics$77K1,177.86N/AN/A$2.21 per share1.09XGNExagen$55.64M2.21N/AN/A$1.33 per share5.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCORBFGlobal Cord Blood$79.04MN/A0.00∞N/AN/AN/AN/AN/AOPGNOpGen-$32.67MN/A0.00∞N/A-1,140.36%N/A-287.58%6/2/2025 (Estimated)SERASera Prognostics-$36.24M-$0.99N/AN/AN/AN/A-51.73%-36.94%5/14/2025 (Estimated)XGNExagen-$23.69M-$0.83N/AN/AN/A-30.36%-92.58%-33.74%5/12/2025 (Estimated)Latest OPGN, CORBF, XGN, and SERA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025XGNExagen-$0.20-$0.20N/A-$0.20$14.55 million$15.50 million5/7/2025Q1 2025SERASera Prognostics-$0.24-$0.20+$0.04-$0.20$0.06 millionN/A3/19/2025Q4 2024SERASera Prognostics-$0.23-$0.25-$0.02-$0.25$0.01 million$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCORBFGlobal Cord BloodN/AN/AN/AN/AN/AOPGNOpGenN/AN/AN/AN/AN/ASERASera PrognosticsN/AN/AN/AN/AN/AXGNExagenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCORBFGlobal Cord BloodN/AN/AN/AOPGNOpGenN/A5.455.45SERASera PrognosticsN/A2.112.11XGNExagen1.544.054.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCORBFGlobal Cord BloodN/AOPGNOpGen2.68%SERASera Prognostics54.64%XGNExagen75.25%Insider OwnershipCompanyInsider OwnershipCORBFGlobal Cord Blood0.50%OPGNOpGen43.80%SERASera Prognostics15.80%XGNExagen26.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCORBFGlobal Cord Blood1,200121.55 millionN/ANot OptionableOPGNOpGen1008.36 million4.70 millionNot OptionableSERASera Prognostics12037.66 million28.44 millionOptionableXGNExagen22018.00 million13.03 millionOptionableOPGN, CORBF, XGN, and SERA HeadlinesRecent News About These CompaniesKeyBanc maintains Exagen stock at Sector WeightMay 7 at 9:03 PM | investing.comKeyBanc maintains Exagen stock at Sector WeightMay 7 at 9:03 PM | investing.comExagen Inc. Announces Proposed Public Offering of Common StockMay 7 at 4:05 PM | globenewswire.comExagen (NASDAQ:XGN) Issues Quarterly Earnings ResultsMay 7 at 9:49 AM | marketbeat.comExagen (XGN) Expected to Announce Earnings on MondayMay 7 at 7:56 AM | marketbeat.comEarnings call transcript: Exagen Inc. Q1 2025 revenue beats forecasts, stock dipsMay 6 at 7:57 PM | uk.investing.comExagen Inc. Reports Record Revenue Amid Strategic GrowthMay 6 at 12:12 AM | tipranks.comExagen Inc. Earnings Call Highlights Record GrowthMay 5 at 8:26 PM | tipranks.comExagen Inc. (XGN) Q1 2025 Earnings Call TranscriptMay 5 at 5:44 PM | seekingalpha.comExagen Inc. (XGN) Reports Q1 Loss, Tops Revenue EstimatesMay 5 at 10:10 AM | zacks.comExagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing VolumeMay 5 at 8:00 AM | globenewswire.comExagen Inc (XGN) Q1 2025 Earnings Report Preview: What To ExpectMay 3, 2025 | finance.yahoo.comPerceptive Advisors Enters $75MM Term Loan Facility with ExagenApril 29, 2025 | abladvisor.comExagen to Raise Up to $75M in Secured Credit FacilityApril 29, 2025 | 360dx.comExagen Inc. Announces Senior Secured Credit Facility with Perceptive AdvisorsApril 28, 2025 | globenewswire.comExagen: Buy An Undervalued Diagnostics Developer That Is On The Path To ProfitabilityApril 26, 2025 | seekingalpha.comInstitutional investors control 30% of Exagen Inc. (NASDAQ:XGN) and were rewarded last week after stock increased 30%April 25, 2025 | finance.yahoo.comExagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025April 21, 2025 | globenewswire.comExagen Inc. (NASDAQ:XGN) Shares Sold by Wasatch Advisors LPApril 20, 2025 | marketbeat.comExagen Inc. (NASDAQ:XGN) Short Interest UpdateApril 16, 2025 | marketbeat.comExagen Inc. (NASDAQ:XGN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?March 14, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOPGN, CORBF, XGN, and SERA Company DescriptionsGlobal Cord Blood NYSE:CORBF$1.09 +0.04 (+3.81%) As of 05/6/2025 10:56 AM EasternGlobal Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.OpGen NASDAQ:OPGN$4.98 -0.17 (-3.30%) As of 01:04 PM EasternOpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.Sera Prognostics NASDAQ:SERA$2.41 -0.11 (-4.44%) Closing price 03:59 PM EasternExtended Trading$2.46 +0.06 (+2.37%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.Exagen NASDAQ:XGN$6.83 +0.41 (+6.39%) Closing price 04:00 PM EasternExtended Trading$5.70 -1.13 (-16.47%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Disney Stock Jumps on Earnings—Is the Magic Sustainable? AMD Relieves Market Despite Ongoing Share Price Outlook Caution Gold’s Record Run in 2025: Here Are 3 Ways to Ride the Surge What the New Quarter Says About Super Micro Computer's Future Archer Stock Eyes Q1 Earnings After UAE Updates Ford Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx Boost Lemonade Delivers Sweet Results, Price Reversal to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
